Business
Karuna Appoints Chief Financial Officer
Karuna Appoints Chief Financial Officer.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 8160R PureTech Health PLC 05 March 2019 \n\n5 March 2019\n \nPureTech Health plc\n \nPureTech Health Affiliate Karuna Announces Appointment of Chief Financial Officer\n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that its affiliate, Karuna Pharmaceuticals, has appointed Mr. Troy Ignelzi as chief financial officer. Mr. Ignelzi brings 25 years of experience to Karuna, having most recently served as chief financial officer of scPharmaceuticals where he led the company's transition from a privately-held, clinical-stage company to a publicly-traded biopharma preparing for commercial launch.\n \nEric Elenko, PhD, chief innovation office at PureTech Health, said: \"Troy is an exceptional addition to Karuna's team, bringing 25 years of financial leadership across mid- to late-stage biotech. We welcome this continued internal growth at Karuna as they advance lead product candidate KarXT through a Phase 2 study for psychosis in schizophrenia.\"\n \nThe full text announcement from Karuna is as follows:\n \nKaruna Strengthens Senior Leadership Team with Appointment of Chief Financial Officer\n \nBOSTON, March 5, 2019-Karuna Pharmaceuticals, Inc. (\"Karuna\"), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment, as well as pain, today announced that Mr. Troy Ignelzi has joined the company as its chief financial officer. Karuna's senior leadership team has been strengthened in recent months with key additions and promotions in its R&D, preclinical and finance functions.\n \n\"We are pleased to welcome Troy to our leadership team. He will play an important role in guiding external financing and internal financial controls as we continue along our next phase of growth,\" said Steve Paul, M.D., chief executive officer and chairman of Karuna. \"As our lead product candidate KarXT advances in clinical development for multiple indications, we plan to continue to expand our leadership team. Troy's experience as CFO at both private and public biotechnology companies will be a considerable asset.\"\n \nMr. Ignelzi has spent 25 years...